{"id":893076,"date":"2025-10-07T07:06:00","date_gmt":"2025-10-07T11:06:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/"},"modified":"2025-10-07T07:06:00","modified_gmt":"2025-10-07T11:06:00","slug":"ocular-therapeutix-to-participate-in-upcoming-scientific-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/","title":{"rendered":"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., Oct.  07, 2025  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025.<\/p>\n<p>\n        <strong>Upcoming Scientific Conferences<\/strong><br \/>\n        <strong> (all times ET):<\/strong>\n      <\/p>\n<p>\n        <strong>American Academy of Optometry:<\/strong> October 8 &#8211; 11, 2025<br \/>Boston, Massachusetts<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial<\/strong><br \/>\n          <br \/>Session Date\/Time:\u00a0Thursday, October 9, 2025, 4:30 \u2013 6:30 PM ET<br \/>Presenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix<\/li>\n<\/ul>\n<p>\n        <strong>Eyecelerator @ AAO 2025<\/strong>: October 16, 2025<br \/>Orlando, Florida<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt\">\n          <strong>Company Presentation: Ocular Therapeutix: Redefining the Retina Experience<\/strong><br \/>\n          <br \/>Session: Presenting Company Showcases<br \/>Session Date\/Time:\u00a0Thursday, October 16, 2025, 1:15 \u2013 2:45 PM ET<br \/>Presenter: Peter K. Kaiser, MD, Chief Development Officer<\/li>\n<\/ul>\n<p>\n        <strong>American Academy of Ophthalmology:<\/strong> October 18 &#8211; 20, 2025<br \/>Orlando, Florida<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>On-Demand Poster Title: Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy<\/strong><br \/>\n          <br \/>Session Date\/Time:\u00a0On-demand posters available for viewing throughout duration of the congress.<br \/>Presenter: Margaret Chang, MD, MS<\/li>\n<\/ul>\n<p>Exact medical conference presentation times may be subject to change.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc.<\/strong>\n      <\/p>\n<p>Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) planned to be initiated imminently.<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.<\/p>\n<p>Explore the Company\u2019s new corporate branding and follow the Company on its website, LinkedIn, or X.<\/p>\n<p>DEXTENZA<sup>\u00ae<\/sup> is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/>bslattery@ocutx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzdlNDc0MzItMzc3My00YmRhLWIzYTgtYzdhMGFlMDM2NDdjLTEwMjI2MjktMjAyNS0xMC0wNy1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025. Upcoming Scientific Conferences (all times ET): American Academy of Optometry: October 8 &#8211; 11, 2025Boston, Massachusetts Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial Session Date\/Time:\u00a0Thursday, October 9, 2025, 4:30 \u2013 6:30 PM ETPresenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix Eyecelerator @ AAO 2025: October 16, 2025Orlando, Florida Company Presentation: Ocular Therapeutix: Redefining the Retina Experience Session: Presenting Company ShowcasesSession Date\/Time:\u00a0Thursday, October 16, 2025, 1:15 \u2013 2:45 PM &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893076","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025. Upcoming Scientific Conferences (all times ET): American Academy of Optometry: October 8 &#8211; 11, 2025Boston, Massachusetts Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial Session Date\/Time:\u00a0Thursday, October 9, 2025, 4:30 \u2013 6:30 PM ETPresenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix Eyecelerator @ AAO 2025: October 16, 2025Orlando, Florida Company Presentation: Ocular Therapeutix: Redefining the Retina Experience Session: Presenting Company ShowcasesSession Date\/Time:\u00a0Thursday, October 16, 2025, 1:15 \u2013 2:45 PM &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T11:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences\",\"datePublished\":\"2025-10-07T11:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/\"},\"wordCount\":384,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=\",\"datePublished\":\"2025-10-07T11:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences - Market Newsdesk","og_description":"BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025. Upcoming Scientific Conferences (all times ET): American Academy of Optometry: October 8 &#8211; 11, 2025Boston, Massachusetts Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial Session Date\/Time:\u00a0Thursday, October 9, 2025, 4:30 \u2013 6:30 PM ETPresenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix Eyecelerator @ AAO 2025: October 16, 2025Orlando, Florida Company Presentation: Ocular Therapeutix: Redefining the Retina Experience Session: Presenting Company ShowcasesSession Date\/Time:\u00a0Thursday, October 16, 2025, 1:15 \u2013 2:45 PM &hellip; Continue reading \"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-07T11:06:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences","datePublished":"2025-10-07T11:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/"},"wordCount":384,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/","name":"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=","datePublished":"2025-10-07T11:06:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTEyNyM3MTgyNzQ4IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-upcoming-scientific-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Participate in Upcoming Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893076"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893076\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}